Dear Editor:
Hemoglobin Barts hydrops fetalis (homozygous α 0 -thalassemia) results from deletion of all four α -globin genes [1] . It was previously considered a universally fatal condition, however, with recent advances in prenatal care and the availability of intrauterine blood transfusions, increasing number of patients are now surviving into adulthood [2] . Similar to patients with transfusiondependent thalassemia due to β -thalassemia (TDT-β) these patients require life-long and regular transfusions, as the option of curative stem cell transplant may not be available for the majority of these patients. Although the Thalassemia International Federation guidelines recommend a transfusion strategy similar to TDT-β for these patients [3] , no report exists on the optimal transfusion management of patients with homozygous α 0 -thalassemia, which could be referred to as transfusion-dependent thalassemia due to α -thalassemia (TDT-α). In TDT-β, initiation of transfusions results in improvement of anemia and suppression of ineffective erythropoiesis, the main underlying pathophysiologic processes.
In early 2014, we critically reviewed the treatment strategy for four patients with homozygous α 0 -thalassemia at our institution who were previously on regular blood transfusions to keep their hemoglobin levels above 100 g/L. On further investigation, hemoglobin analysis (by high-performance liquid chromatography (HPLC) and capillary zone electrophoresis) showed hemoglobin H (Hb H) percentage ranging from 24% to 64% in our patients with older patients having higher Hb H.
Hemoglobin H, a tetramer of four β -globin chains, has extremely high oxygen affinity and poor tissue oxygen delivery making it essentially non-functional [4] [5] [6] . With the high Hb H levels observed in our chronically transfused patients with homozygous α 0 -thalassemia, we estimated the patients' "functional" hemoglobin as total hemoglobin x (1 -Hb H% /100), which ranged from 42.7 to 79.0 g/L.
To improve tissue oxygenation and suppress hemolysis, we elected to modify our transfusion strategy by aggressively suppressing endogenous erythropoiesis with a goal to reduce Hb H percentage to less than 15% and to keep the "functional" hemoglobin above 100 g/L in our patients. These targets were chosen to correspond to the average Hb H levels observed in patients with hemoglobin-H disease and the recommended pre-transfusion hemoglobin level in TDT-β patients. To achieve these targets, three patients with Hb H levels of more than 25% also Suboptimal transfusions (with associated anemia and hypoxia) as well as severe hemolysis have been shown to be associated with a variety of significant clinical sequelae in β thalassemia patients and in other disorders [8] [9] [10] . Here, we demonstrate that in patients with homozygous α 0 -thalassemia (TDT-α), a transfusion strategy similar to those of TDT-β patients does not adequately ameliorate the underlying hemolytic process and the poor tissue oxygen delivery over time, making this approach suboptimal for the management of these patients.
While we are yet to demonstrate any long-term clinical benefits to these patients (which would require a longer duration of regular transfusions), a more intensive transfusion regimen targeted at reducing Hb H levels resulting in an increased "functional" hemoglobin, reduced tissue hypoxia and hemolysis seems more appropriate for patients with homozygous α 0 -thalassemia. Characteristics of four homozygous α 0 -thalassemia patients who are being followed in our institution. All patients provided consent for publication of this report. One patient (data not shown) was born after the implementation of new transfusion strategy and has been transfused based on the new regimen since birth.
Splenectomy has been associated with reduced transfusion requirements in TDT
1, Patients' hemoglobin analysis was performed via high performance liquid chromatography (HPLC) and confirmed using capillary zone electrophoresis. 2, Spleen size was measured on ultrasonography.
Hb: Hemoglobin, MRI: magnetic resonance imaging. SEA: Southeast Asian deletion. 
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